ArticleLupus science & medicine2026
Development of a LASSO-based machine learning model for relapse prediction in lupus nephritis.
Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify the predictors of renal relapse in patients with lupus nephritis (LN) and develop a predictive model.
methodsThe patients with LN who received renal biopsies from 2005 to 2024 in Xijing Hospital were enrolled. This study was designed as a cohort study. Clinical and serological characteristics at the time of renal biopsy, nephritis histology, the duration to remission and treatment regimen were evaluated. Variables were screened using least absolute shrinkage and selection operator (LASSO)-Cox analyses, followed by the application of multivariate Cox regression to construct a relapse risk prediction model. The performance of the model was evaluated using bootstrap resampling. A landmark analysis was performed at 12 months, excluding patients who relapsed within this period. The model is intended for application at the 12-month postbiopsy time point.
resultsA total of 831 patients were enrolled in the study, 225/831 patients (27.08%) experienced relapse. Compared with the patients without relapse, patients with relapse demonstrated younger age of onset (24.0 vs 27.0 years, p=0.001), higher SLE Disease Activity Index (SLEDAI) (12.0 vs 7.0, p=0.001) and proteinuria (1.2 vs 0.6 g/day, p=0.001). However, the nephritis histology showed no significant difference between the two groups. The proportion of patients receiving intravenous methylprednisolone pulse therapy or belimumab in the non-relapse group was significantly higher. Using LASSO-Cox regression, four variables associated with LN relapse were identified, including level of 24-hour proteinuria, SLEDAI 2000 (SLEDAI-2K), low complement C3 level and remission within 12 months. The predictive model exhibited good predictive performance, with a bootstrap-corrected C-index of 0.75 (95% CI 0.72 to 0.79).
conclusionsHigher level of 24-hour proteinuria, higher SLEDAI-2K score and low complement C3 level were risk factors for LN relapse, while remission within 12 months was a protective factor. The LASSO-Cox-based predictive model exhibited good performance and may serve as a useful tool for the clinical management of LN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.